JP2024096330A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2024096330A5 JP2024096330A5 JP2024074907A JP2024074907A JP2024096330A5 JP 2024096330 A5 JP2024096330 A5 JP 2024096330A5 JP 2024074907 A JP2024074907 A JP 2024074907A JP 2024074907 A JP2024074907 A JP 2024074907A JP 2024096330 A5 JP2024096330 A5 JP 2024096330A5
- Authority
- JP
- Japan
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GB1611123.9 | 2016-06-27 | ||
| GBGB1611123.9A GB201611123D0 (en) | 2016-06-27 | 2016-06-27 | Anti met antibodiesand uses thereof |
| JP2018569021A JP7088853B2 (ja) | 2016-06-27 | 2017-06-23 | 抗ｍｅｔ抗体とその利用 |
| PCT/EP2017/065599 WO2018001909A1 (en) | 2016-06-27 | 2017-06-23 | Anti-met antibodies and uses thereof |
| JP2022093880A JP7546834B2 (ja) | 2016-06-27 | 2022-06-09 | 抗ｍｅｔ抗体とその利用 |
Related Parent Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022093880A Division JP7546834B2 (ja) | 2016-06-27 | 2022-06-09 | 抗ｍｅｔ抗体とその利用 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2024096330A JP2024096330A (ja) | 2024-07-12 |
| JP2024096330A5 true JP2024096330A5 (enExample) | 2024-08-26 |
Family
ID=56891586
Family Applications (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2018569021A Active JP7088853B2 (ja) | 2016-06-27 | 2017-06-23 | 抗ｍｅｔ抗体とその利用 |
| JP2022093880A Active JP7546834B2 (ja) | 2016-06-27 | 2022-06-09 | 抗ｍｅｔ抗体とその利用 |
| JP2024074907A Pending JP2024096330A (ja) | 2016-06-27 | 2024-05-02 | 抗ｍｅｔ抗体とその利用 |
Family Applications Before (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2018569021A Active JP7088853B2 (ja) | 2016-06-27 | 2017-06-23 | 抗ｍｅｔ抗体とその利用 |
| JP2022093880A Active JP7546834B2 (ja) | 2016-06-27 | 2022-06-09 | 抗ｍｅｔ抗体とその利用 |
Country Status (13)
| Country | Link |
|---|---|
| US (3) | US11098126B2 (enExample) |
| EP (2) | EP3475302A1 (enExample) |
| JP (3) | JP7088853B2 (enExample) |
| KR (3) | KR102566845B1 (enExample) |
| CN (3) | CN120005025A (enExample) |
| AU (2) | AU2017288985B2 (enExample) |
| BR (1) | BR112018077139A8 (enExample) |
| CA (2) | CA3032496A1 (enExample) |
| GB (1) | GB201611123D0 (enExample) |
| MX (1) | MX2019000135A (enExample) |
| NZ (4) | NZ789717A (enExample) |
| RU (2) | RU2765267C2 (enExample) |
| WO (1) | WO2018001909A1 (enExample) |
Families Citing this family (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| IT201800000534A1 (it) * | 2018-01-03 | 2019-07-03 | Procedimenti per la promozione della crescita cellulare degli isolotti pancreatici. | |
| GB201611123D0 (en) | 2016-06-27 | 2016-08-10 | Euremab Srl | Anti met antibodiesand uses thereof |
| IT201800000535A1 (it) | 2018-01-03 | 2019-07-03 | Procedimenti per la cura del cancro. | |
| KR102221755B1 (ko) * | 2018-05-02 | 2021-03-02 | (주)에임드바이오 | c-Met에 특이적으로 결합하는 항체 및 그의 용도 |
| SG11202108311RA (en) | 2019-02-26 | 2021-09-29 | Janssen Biotech Inc | Combination therapies and patient stratification with bispecific anti-egfr/c-met antibodies |
| US11879013B2 (en) | 2019-05-14 | 2024-01-23 | Janssen Biotech, Inc. | Combination therapies with bispecific anti-EGFR/c-Met antibodies and third generation EGFR tyrosine kinase inhibitors |
| JOP20220184A1 (ar) | 2020-02-12 | 2023-01-30 | Janssen Biotech Inc | علاج مصابي السرطان ممن لديهم طفرات تخطي c-Met إكسون14 |
| JP2024515266A (ja) | 2021-04-08 | 2024-04-08 | ビョンディス・ビー．ブイ． | 抗ｃ－ＭＥＴ抗体及び抗体薬物複合体 |
| EP4340937A1 (en) | 2021-05-21 | 2024-03-27 | Emblation Limited | Microwave treatment of tissue |
| WO2025163490A1 (en) * | 2024-01-30 | 2025-08-07 | University Of Pittsburgh - Of The Commonwealth System Of Higher Education | Growth factor receptor agonist/antagonist |
Family Cites Families (31)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5892019A (en) | 1987-07-15 | 1999-04-06 | The United States Of America, As Represented By The Department Of Health And Human Services | Production of a single-gene-encoded immunoglobulin |
| US5587309A (en) | 1994-04-29 | 1996-12-24 | The United States Of America As Represented By The Department Of Health And Human Services | Method of stimulating proliferation and differentiation of human fetal pancreatic cells ex vivo |
| US5686292A (en) | 1995-06-02 | 1997-11-11 | Genentech, Inc. | Hepatocyte growth factor receptor antagonist antibodies and uses thereof |
| DE69739856D1 (de) | 1996-07-03 | 2010-06-02 | Genentech Inc | Agonisten für den rezeptor des hepatozyten-wachstumsfaktors und deren anwendungen |
| WO2001093899A1 (en) | 2000-06-02 | 2001-12-13 | Hiroshi Okamoto | PANCREATIC LANGERHANS β CELL PROLIFERATION PROMOTER AND APOPTOSIS INHIBITOR, AND SCREENING OF CANDIDATE COMPOUNDS FOR THE E DRUGS |
| GB0110430D0 (en) | 2001-04-27 | 2001-06-20 | Medical Res Council | Protein variants and uses thereof |
| PL204899B1 (pl) | 2001-05-23 | 2010-02-26 | Bristol Myers Squibb Co | Zastosowanie rozpuszczalnej zmutowanej cząsteczki CTLA4 |
| ITMI20031127A1 (it) | 2003-06-05 | 2004-12-06 | Uni Degli Studi Del Piemont E Orientale Am | Anticorpi anti-hgf-r e loro uso |
| HN2004000285A (es) | 2003-08-04 | 2006-04-27 | Pfizer Prod Inc | ANTICUERPOS DIRIGIDOS A c-MET |
| JP5068651B2 (ja) * | 2004-08-05 | 2012-11-07 | ジェネンテック， インコーポレイテッド | ヒト化抗ｃｍｅｔ抗体 |
| DK1981981T3 (da) * | 2006-02-06 | 2011-09-26 | Metheresis Translational Res Sa | Monoklonalt anti-met antistof, fragmenter og vektorer deraf til behandling af tumorer, samt tilsvarende produkter |
| AU2011203499B2 (en) | 2006-03-30 | 2013-01-31 | Novartis Ag | Compositions and methods of use for antibodies of c-Met |
| WO2008111464A1 (ja) * | 2007-03-05 | 2008-09-18 | Eisai R & D Management Co., Ltd. | スプライシング異常を指標とする抗ガン剤の作用検定方法 |
| GB2461546B (en) | 2008-07-02 | 2010-07-07 | Argen X Bv | Antigen binding polypeptides |
| US20120190668A1 (en) | 2009-08-12 | 2012-07-26 | Oehlen Lambertus J W M | Enhancement of cellular transplantation using small moleucle modulators of hepatocyte growth factor (scatter factor) activity |
| GB2476681B (en) | 2010-01-04 | 2012-04-04 | Argen X Bv | Humanized camelid VH, VK and VL immunoglobulin domains |
| WO2011150454A1 (en) * | 2010-06-01 | 2011-12-08 | Monash University | ANTIBODIES DIRECTED TO THE UNPROCESSED RECEPTOR TYROSINE KINASE c-MET |
| BR122014027420A2 (pt) * | 2010-11-03 | 2019-08-20 | Argenx Bvba | Anticorpos anti c-met |
| DK2686347T3 (en) * | 2011-03-16 | 2018-06-25 | Argenx Bvba | Antibodies against CD70 |
| WO2012138599A2 (en) | 2011-04-02 | 2012-10-11 | Washington State University Research Foundation | Hepatocyte growth factor mimics as therapeutic agents |
| KR101444837B1 (ko) | 2011-06-03 | 2014-09-30 | 한국생명공학연구원 | ＨＧＦ 활성을 가지는 ｃ-Ｍｅｔ에 대한 인간항체 및 이의 용도 |
| KR20130036993A (ko) | 2011-10-05 | 2013-04-15 | 삼성전자주식회사 | ｃ-Ｍｅｔ의 ＳＥＭＡ 도메인 내의 에피토프에 특이적으로 결합하는 항체 |
| GB201121914D0 (en) * | 2011-12-20 | 2012-02-01 | Ge Healthcare Ltd | Method for patient selection |
| WO2013175276A1 (en) * | 2012-05-23 | 2013-11-28 | Argen-X B.V | Il-6 binding molecules |
| KR101615619B1 (ko) | 2014-08-07 | 2016-04-26 | 주식회사 파멥신 | c-Met 특이적 인간 항체 및 그 제조방법 |
| CA2972048C (en) | 2014-12-22 | 2023-03-07 | The Rockefeller University | Anti-mertk agonistic antibodies and uses thereof |
| CN105087468B (zh) | 2015-09-01 | 2018-12-07 | 东南大学 | 一种高效诱导干细胞向胰岛β样细胞分化的方法 |
| KR102476846B1 (ko) | 2016-02-05 | 2022-12-12 | 주식회사 헬릭스미스 | 항―ｃ―ＭＥＴ 항체 및 이의 용도 |
| IT201800000534A1 (it) | 2018-01-03 | 2019-07-03 | Procedimenti per la promozione della crescita cellulare degli isolotti pancreatici. | |
| GB201611123D0 (en) | 2016-06-27 | 2016-08-10 | Euremab Srl | Anti met antibodiesand uses thereof |
| IT201800000535A1 (it) | 2018-01-03 | 2019-07-03 | Procedimenti per la cura del cancro. |
-
2016
- 2016-06-27 GB GBGB1611123.9A patent/GB201611123D0/en not_active Ceased
-
2017
- 2017-06-23 NZ NZ789717A patent/NZ789717A/en unknown
- 2017-06-23 NZ NZ789725A patent/NZ789725A/en unknown
- 2017-06-23 MX MX2019000135A patent/MX2019000135A/es unknown
- 2017-06-23 KR KR1020227005547A patent/KR102566845B1/ko active Active
- 2017-06-23 WO PCT/EP2017/065599 patent/WO2018001909A1/en not_active Ceased
- 2017-06-23 CN CN202510170332.2A patent/CN120005025A/zh active Pending
- 2017-06-23 NZ NZ789721A patent/NZ789721A/en unknown
- 2017-06-23 CN CN201780040456.2A patent/CN109689687B/zh active Active
- 2017-06-23 CA CA3032496A patent/CA3032496A1/en active Pending
- 2017-06-23 AU AU2017288985A patent/AU2017288985B2/en active Active
- 2017-06-23 RU RU2018146419A patent/RU2765267C2/ru active
- 2017-06-23 CA CA3260141A patent/CA3260141A1/en active Pending
- 2017-06-23 KR KR1020197002631A patent/KR102366667B1/ko active Active
- 2017-06-23 NZ NZ749578A patent/NZ749578A/en unknown
- 2017-06-23 JP JP2018569021A patent/JP7088853B2/ja active Active
- 2017-06-23 RU RU2022101369A patent/RU2022101369A/ru unknown
- 2017-06-23 CN CN202210749235.5A patent/CN115057933B/zh active Active
- 2017-06-23 EP EP17735419.8A patent/EP3475302A1/en active Pending
- 2017-06-23 KR KR1020237027102A patent/KR102686694B1/ko active Active
- 2017-06-23 BR BR112018077139A patent/BR112018077139A8/pt active IP Right Grant
- 2017-06-23 US US16/313,710 patent/US11098126B2/en active Active
- 2017-06-23 EP EP19202060.0A patent/EP3674321A3/en active Pending
-
2021
- 2021-08-09 US US17/397,510 patent/US12084504B2/en active Active
-
2022
- 2022-06-09 JP JP2022093880A patent/JP7546834B2/ja active Active
-
2023
- 2023-12-13 US US18/538,107 patent/US20240228632A9/en active Pending
-
2024
- 2024-05-02 JP JP2024074907A patent/JP2024096330A/ja active Pending
- 2024-08-12 AU AU2024205680A patent/AU2024205680A1/en active Pending